Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases

Abdeladim, Salma; Elharras, Mahassine; Elouarradi, Amal; Bensahi, Ilham; Oualim, Sara; Merzouk, Fatimazahra; Sabry, Mohamed

doi:10.11604/pamj.2021.38.9.27215

Cited by 6 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that GP IIb/IIIa receptor antagonists can cause diffuse alveolar hemorrhage, [ 7 ] which can be life-threatening. Salma Abdeladim et al [ 8 ] reported 2 patients who experienced extremely severe thrombocytopenia and massive bleeding after emergency coronary intervention with tirofiban and unfractionated heparin. Amit Gulati et al [ 9 ] also reported a case of thrombocytopenia with platelet count dropping to 4 × 10 9 /L within 1 day after tirofiban administration.…”

Section: Discussionmentioning

confidence: 99%

A case report of acute myocardial infarction with extremely severe thrombocytopenia after percutaneous coronary intervention

Chen,

Wang,

Ning

2023

Medicine

View full text Add to dashboard Cite

Introduction: The case report’s purpose is to remind doctors a rare complication named thrombocytopenia of antithrombotic drugs. As a result, severe bleeding or even life-threatening situations may be avoided. Patient concerns: A specific case of a patient with acute myocardial infarction, a significant decrease in platelet count was observed after percutaneous coronary intervention. Diagnosis: After ruling out other potential causes, the medical team considered tirofiban-induced thrombocytopenia as a possible explanation. Interventions and outcomes: Through careful monitoring and adjustment of medication, the patient’s platelet count eventually returned to normal. Conclusion: To ensure patient safety, it is advised to regularly monitor platelet counts at intervals of 2 to 6 hours before and after administering tirofiban.

show abstract

Section: Discussionmentioning

confidence: 99%